Wolfe Research upgraded shares of AnaptysBio (NASDAQ:ANAB - Free Report) to a strong-buy rating in a report issued on Monday morning, Marketbeat Ratings reports.
Several other research firms have also commented on ANAB. HC Wainwright restated a "neutral" rating and set a $19.00 price target on shares of AnaptysBio in a research report on Tuesday. BTIG Research downgraded shares of AnaptysBio from a "buy" rating to a "neutral" rating in a report on Monday, December 2nd. Wells Fargo & Company decreased their price objective on shares of AnaptysBio from $56.00 to $40.00 and set an "overweight" rating on the stock in a report on Thursday, December 12th. Guggenheim decreased their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a report on Thursday, December 12th. Finally, UBS Group increased their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $40.08.
View Our Latest Stock Report on ANAB
AnaptysBio Stock Performance
NASDAQ:ANAB traded down $1.50 during midday trading on Monday, reaching $14.58. 522,893 shares of the stock traded hands, compared to its average volume of 685,341. AnaptysBio has a 12-month low of $12.51 and a 12-month high of $41.31. The business has a 50-day moving average of $16.48 and a two-hundred day moving average of $26.47. The stock has a market capitalization of $443.67 million and a PE ratio of -2.40.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating analysts' consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million during the quarter, compared to analysts' expectations of $7.92 million. Research analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current year.
Insider Buying and Selling at AnaptysBio
In other AnaptysBio news, Director Ecor1 Capital, Llc acquired 6,646 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the acquisition, the director now owns 7,880,094 shares of the company's stock, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 33.70% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in ANAB. The Manufacturers Life Insurance Company grew its holdings in shares of AnaptysBio by 49.8% in the second quarter. The Manufacturers Life Insurance Company now owns 25,312 shares of the biotechnology company's stock valued at $634,000 after purchasing an additional 8,418 shares in the last quarter. Algert Global LLC lifted its stake in AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company's stock worth $255,000 after acquiring an additional 1,078 shares during the last quarter. SG Americas Securities LLC purchased a new position in AnaptysBio in the third quarter worth approximately $405,000. nVerses Capital LLC lifted its stake in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock worth $54,000 after acquiring an additional 1,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company's stock worth $15,927,000 after acquiring an additional 168,813 shares during the last quarter.
About AnaptysBio
(
Get Free Report)
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Featured Articles
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
